Case Series of Chronic Inflammatory Rheumatic Disease Patients Infected by Coronavirus Disease 2019 (COVID-19)

Tiendrébéogo, W. Joëlle S.; Kaboré, Fulgence; Diendéré, Eric Arnaud; Ouédraogo, Dieu-Donné

doi:10.1155/2020/8860492

Cited by 5 publications

(2 citation statements)

References 14 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, patients with mutivisceral SLE damage would be at risk of severe COVID-19. 52 , 55 A patient of SLE with COVID-19 could develop COVID‐19–related varicelliform rashes, leptomeningeal involvements, thrombotic events and immune thrombocytopenia. 9 , 20 , 28 , 33 , 35 , 48 The infection of COVID-19 could trigger the presentation or exacerbation of SLE.…”

Section: Resultsmentioning

confidence: 99%

COVID-19 in patients with systemic lupus erythematosus: A systematic review

Qian

Jin

et al. 2022

Lupus

View full text Add to dashboard Cite

The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19 in patients with systemic lupus erythematosus: A systematic review

Qian

Jin

et al. 2022

Lupus

View full text Add to dashboard Cite

show abstract

“…There were 17 case reports [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] and 7 case series 4,[27][28][29][30][31][32] included. The patients reported in 9 of the articles originated from Asia, 4,10,12,14,16,21,26,27,29 3 from Europe, 24,25,31 8 from North America, 11,13,15,17,19,22,23 2 from Africa, 20,30 and 2 from South America. 28,32 The case series had 3-6 patients.…”

Section: Selected Articlesmentioning

confidence: 99%

COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series

Sakthiswary

Chuah

Chiang

et al. 2021

Lupus

View full text Add to dashboard Cite

Objective In the recent months, there have been several case reports and case series on COVID-19 in patients with systemic lupus erythematosus(SLE). We conducted a pooled analysis and systematic review to summarise the findings of these articles. Besides, we aimed to determine the predictors of severe COVID-19 infection in SLE by comparing the mild to moderate cases with the severe to critical ones. Method All case reports and case series pertaining to COVID-19 in SLE were retrieved from Pubmed, Wiley Online Library, Springer Link, Science Direct and Web of Science databases using ‘lupus’, ‘systemic lupus erythematosus’, ‘coronavirus’, ‘SARS-CoV-2’, ‘SLE’ and “Covid-19” as keywords. The following data were extracted from the selected articles: country, age of the patient and the characteristics of SLE such as disease duration, organ or system involved, baseline medications and the severity of the COVID-19 infection. Data extracted from the articles were utilised to perform the pooled analysis. Results A total of 24 articles with 48 patients met the eligibility criteria. The median age at diagnosis of COVID-19 infection was 41 years (IQR: 11–66 years). The median SLE disease duration prior to the diagnosis of COVID-19 was 9 years (IQR: 0–30 years). A total of 22 (45.83%) patients had severe to critical COVID-19. This pooled data did not demonstrate any difference in the baseline medications between the 2 groups. Patients with lupus nephritis were significantly more prone to develop severe to critical disease ( p = 0 .036) with an odds ratio of 5.40 (95% confidence interval of 1.120–26.045). Conclusion We found that lupus nephritis was the only predictor of severe to critical COVID-19 in SLE.

show abstract